Literature DB >> 11468958

A policy analysis of major decisions relating to Creutzfeldt-Jakob disease and the blood supply.

K Wilson1, P C Hébert, A Laupacis, C Dornan, M Ricketts, N Ahmad, I Graham.   

Abstract

Creutzfeldt-Jakob disease (CJD) is the first major challenge that the blood system has faced since the completion of the Krever inquiry in 1997. We report the results of a detailed policy analysis comparing 2 CJD-related decisions: a 1995 recall of blood from a donor with classic CJD and the 1999 decision to defer donations from individuals with a 6-month travel history to the UK between 1980 and 1996 due to concerns related to variant CJD. Overall, we observed that decision-making improved significantly from 1995 to 1999. In 1998/99 the potential threat of variant CJD was identified at an early stage, and a systematic risk assessment process was initiated. Decision-making was consultative and involved consumers. However, the perception existed that further improvement could take place in the areas of transparency of process and interaction of organizations. We observed that the presence of a second operator had an important impact on decision-making in 1998/99.

Entities:  

Mesh:

Year:  2001        PMID: 11468958      PMCID: PMC81247     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  4 in total

1.  France prepares for more cases of vCJD.

Authors:  A Dorozynski
Journal:  BMJ       Date:  2000-11-18

Review 2.  Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies.

Authors:  K Wilson; C Code; M N Ricketts
Journal:  BMJ       Date:  2000-07-01

3.  Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent.

Authors:  M E Bruce; R G Will; J W Ironside; I McConnell; D Drummond; A Suttie; L McCardle; A Chree; J Hope; C Birkett; S Cousens; H Fraser; C J Bostock
Journal:  Nature       Date:  1997-10-02       Impact factor: 49.962

4.  A new variant of Creutzfeldt-Jakob disease in the UK.

Authors:  R G Will; J W Ironside; M Zeidler; S N Cousens; K Estibeiro; A Alperovitch; S Poser; M Pocchiari; A Hofman; P G Smith
Journal:  Lancet       Date:  1996-04-06       Impact factor: 79.321

  4 in total
  7 in total

1.  The challenge of an increasingly expensive blood system.

Authors:  Kumanan Wilson; Paul C Hébert
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

2.  The Krever Commission--10 years later.

Authors:  Kumanan Wilson
Journal:  CMAJ       Date:  2007-11-20       Impact factor: 8.262

3.  Do expert assessments converge? An exploratory case study of evaluating and managing a blood supply risk.

Authors:  John Eyles; Nancy Heddle; Kathryn Webert; Emmy Arnold; Bronwen McCurdy
Journal:  BMC Public Health       Date:  2011-08-24       Impact factor: 3.295

4.  Problems with precaution: the transfusion medicine experience.

Authors:  Kumanan Wilson; Katherine M Atkinson; Dean A Fergusson; Adalsteinn Brown; Alan Forster; Malia S Q Murphy; Alan T Tinmouth; Jennifer Keelan
Journal:  J Risk Res       Date:  2017-07-29

5.  Variant Creutzfeldt-Jakob disease and the Canadian blood system after the tainted blood tragedy.

Authors:  Kumanan Wilson; Ian Graham; Maura Ricketts; Christopher Dornan; Andreas Laupacis; Paul Hebert
Journal:  Soc Sci Med       Date:  2006-10-02       Impact factor: 4.634

6.  The reporting of theoretical health risks by the media: Canadian newspaper reporting of potential blood transmission of Creutzfeldt-Jakob disease.

Authors:  Kumanan Wilson; Catherine Code; Christopher Dornan; Nadya Ahmad; Paul Hébert; Ian Graham
Journal:  BMC Public Health       Date:  2004-01-05       Impact factor: 3.295

7.  Pandemic H1N1 in Canada and the use of evidence in developing public health policies--a policy analysis.

Authors:  Laura C Rosella; Kumanan Wilson; Natasha S Crowcroft; Anna Chu; Ross Upshur; Donald Willison; Shelley L Deeks; Brian Schwartz; Jordan Tustin; Doug Sider; Vivek Goel
Journal:  Soc Sci Med       Date:  2013-02-13       Impact factor: 4.634

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.